Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4(+) and CD8(+) T Cells and Counteracts the Induction of Type 1 Regulatory T Cells

The purpose of the present study was to broaden the knowledge and understanding of the effects of oclacitinib (OCL), a Janus kinase inhibitor, on T cells in the context of both the immune mechanisms underlying anti-inflammatory and anti-allergic properties of the drug and its safety. The results ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasiecka-Mikołajczyk, Agnieszka, Jaroszewski, Jerzy J., Maślanka, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472008/
https://www.ncbi.nlm.nih.gov/pubmed/34577127
http://dx.doi.org/10.3390/molecules26185655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472008/
https://www.ncbi.nlm.nih.gov/pubmed/34577127
http://dx.doi.org/10.3390/molecules26185655

Ejemplares similares